ErbB-3 Receptor Immunotherapy Using Codon-Optimized Plasmid DNA
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments targeting the ErbB receptor family, particularly EGFR and HER2, face limitations due to resistance mechanisms mediated by HER3, which are challenging to inhibit effectively with existing monoclonal antibodies and vaccines, leading to suboptimal clinical efficacy and resistance in cancer therapies.
Innovation Solution
Development of a nucleic acid-based genetic vaccine using codon-optimized plasmid DNA encoding a mutant form of the ErbB3 receptor and monoclonal antibodies targeting specific epitopes on the ErbB3 protein, designed to induce a robust immune response and block the oncogenic activity of HER3, potentially overcoming resistance mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing monoclonal antibodies and vaccines targeting EGFR and HER2 are used, then some tumor growth inhibition is achieved, but resistance mechanisms mediated by HER3 overexpression and activation reduce clinical efficacy
Solution Approach 1:
The patent extracts and targets HER3 specifically, separating it from the traditional EGFR/HER2 targeting approach. By developing antibodies and vaccines that specifically recognize HER3 epitopes, the invention isolates the resistance mechanism (HER3 overexpression) and creates therapies directed against it, thereby overcoming the limitation of existing therapies that cannot effectively inhibit HER3-mediated signaling.
Solution Approach 2:
Instead of targeting the classic EGFR/HER2 pathways that are already well-established, the patent inverts the approach by focusing on HER3, which has been overlooked despite its critical role in resistance. This inversion of the traditional targeting strategy reveals a new therapeutic avenue that addresses the resistance problem caused by HER3 overexpression.
2Reliability
If HER3 is overexpressed and activated in tumors, then signaling pathways for proliferation and survival are enhanced, but current therapies lack effective inhibitors against HER3
Solution Approach 1:
The patent uses codon-optimized plasmid DNA that copies and expresses HER3 protein sequences with enhanced accuracy and efficiency. The plasmid contains optimized codon sequences that ensure proper folding and conformation of the HER3 protein, enabling the immune system to recognize and respond effectively to HER3 epitopes, thereby facilitating the development of effective HER3-targeted therapies.
Solution Approach 2:
The patent applies parameter changes by optimizing the codon usage in the plasmid DNA sequence to match the host organism's preferences. This optimization enhances protein expression levels and proper folding, which are critical parameters for generating sufficient HER3 antigen for immune recognition and antibody production, thereby improving therapeutic efficacy.
3Reliability
If peptide and protein-based vaccines against HER2 are used, then cell-mediated immune response is induced, but they fail to control metastasis diffusion in human patients
Solution Approach 1:
The patent replaces traditional peptide and protein-based vaccine approaches with a plasmid DNA-based vaccination system. This substitution enables the delivery of genetic information that instructs host cells to produce HER3 protein, thereby inducing both cell-mediated and antibody responses. The plasmid DNA approach simplifies the vaccine design by using a single molecular carrier that can encode multiple antigens and elicit comprehensive immune responses, addressing the limitations of previous vaccine designs.
Solution Approach 2:
The plasmid DNA vaccine platform exhibits multi-functionality by capable of inducing multiple types of immune responses simultaneously - both cell-mediated immunity and antibody production. This universal approach allows a single vaccine formulation to target HER3 and potentially other cancer antigens, providing a versatile platform that overcomes the limitations of peptide-based vaccines which primarily elicit cell-mediated responses.
4Reliability
If trastuzumab and CTLs are combined for treatment, then tumor cell lysis is enhanced, but the diffusion of metastasis remains uncontrolled
Solution Approach 1:
The patent applies preliminary anti-action by pre-vaccinating patients with HER3-specific plasmid DNA to induce protective antibody responses and cell-mediated immunity before the actual cancer treatment. This preliminary immune priming creates a state of readiness where the immune system can rapidly respond to and eliminate HER3-positive tumor cells and metastases, thereby preventing metastasis diffusion while enhancing tumor cell lysis during combination therapy with trastuzumab and CTLs.
Data Source
Figure 1A~1C
Figure 2A~2B
Figure 3A~3B
AI summary
The present invention describes methods and pharmaceutical compositions for the treatment of cancer in mammals, more particularly in human subjects. More specifically, the invention concerns anti-tumor vaccines based upon plasmid DNA and/or genetic vectors carrying a codon-usage optimized sequence and coding for a mutant form of the ErbB-3 receptor. Furthermore, the invention refers to monoclonal antibodies directed against the ErbB-3 receptor, obtained using these methods and capable to block its activity in cancer cells.